These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Pro-resolving mediators promote resolution in a human skin model of UV-killed Escherichia coli-driven acute inflammation. Motwani MP; Colas RA; George MJ; Flint JD; Dalli J; Richard-Loendt A; De Maeyer RP; Serhan CN; Gilroy DW JCI Insight; 2018 Mar; 3(6):. PubMed ID: 29563331 [TBL] [Abstract][Full Text] [Related]
29. Resolvin D1 attenuates imiquimod-induced mice psoriasiform dermatitis through MAPKs and NF-κB pathways. Xu J; Duan X; Hu F; Poorun D; Liu X; Wang X; Zhang S; Gan L; He M; Zhu K; Ming Z; Chen H J Dermatol Sci; 2018 Feb; 89(2):127-135. PubMed ID: 29137840 [TBL] [Abstract][Full Text] [Related]
30. Omega-3 Polyunsaturated Fatty Acids in Critical Illness: Anti-Inflammatory, Proresolving, or Both? Molfino A; Amabile MI; Monti M; Muscaritoli M Oxid Med Cell Longev; 2017; 2017():5987082. PubMed ID: 28694914 [TBL] [Abstract][Full Text] [Related]
32. Cutting Edge: Human Vagus Produces Specialized Proresolving Mediators of Inflammation with Electrical Stimulation Reducing Proinflammatory Eicosanoids. Serhan CN; de la Rosa X; Jouvene CC J Immunol; 2018 Dec; 201(11):3161-3165. PubMed ID: 30355784 [TBL] [Abstract][Full Text] [Related]
33. The effects of alcohol on plasma lipid mediators of inflammation resolution in patients with Type 2 diabetes mellitus. Barden A; Shinde S; Phillips M; Beilin L; Mas E; Hodgson JM; Puddey I; Mori TA Prostaglandins Leukot Essent Fatty Acids; 2018 Jun; 133():29-34. PubMed ID: 29789130 [TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics and Changes in Lipid Mediator Profiling after Consumption of Specialized Pro-Resolving Lipid-Mediator-Enriched Marine Oil in Healthy Subjects. Irún P; Carrera-Lasfuentes P; Sánchez-Luengo M; Belio Ú; Domper-Arnal MJ; Higuera GA; Hawkins M; de la Rosa X; Lanas A Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003333 [TBL] [Abstract][Full Text] [Related]
36. Neuromodulation, Specialized Proresolving Mediators, and Resolution of Pain. Tao X; Lee MS; Donnelly CR; Ji RR Neurotherapeutics; 2020 Jul; 17(3):886-899. PubMed ID: 32696274 [TBL] [Abstract][Full Text] [Related]
37. A randomized controlled trial of the effects of n-3 fatty acids on resolvins in chronic kidney disease. Mas E; Barden A; Burke V; Beilin LJ; Watts GF; Huang RC; Puddey IB; Irish AB; Mori TA Clin Nutr; 2016 Apr; 35(2):331-336. PubMed ID: 25908532 [TBL] [Abstract][Full Text] [Related]
38. Lipid mediators in the resolution of inflammation. Serhan CN; Chiang N; Dalli J; Levy BD Cold Spring Harb Perspect Biol; 2014 Oct; 7(2):a016311. PubMed ID: 25359497 [TBL] [Abstract][Full Text] [Related]
39. Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Serhan CN Annu Rev Immunol; 2007; 25():101-37. PubMed ID: 17090225 [TBL] [Abstract][Full Text] [Related]
40. Molecular Pharmacology of Inflammation Resolution in Atherosclerosis. Kotlyarov S; Kotlyarova A Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563200 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]